These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38310500)

  • 1. US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation.
    Matthews KRW; Lowe SJ; Master Z
    Cytotherapy; 2024 Apr; 26(4):404-409. PubMed ID: 38310500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Academic physician specialists' views toward the unproven stem cell intervention industry: areas of common ground and divergence.
    Smith C; Crowley A; Munsie M; DeMartino ES; Staff NP; Shapiro S; Master Z
    Cytotherapy; 2021 Apr; 23(4):348-356. PubMed ID: 33563545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.
    Ogbogu U; Du J; Koukio Y
    BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Texas H.B. 810: Increased Access to Stem Cell Interventions or an Increase in Unproven Treatments?
    Matthews K; Kunisetty B; Sprung K
    Stem Cells Dev; 2018 Nov; 27(21):1463-1465. PubMed ID: 30122128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing persuasive health education for patients seeking unproven stem cell interventions.
    Kawam O; Zhu X; Eton DT; Martin-Lillie C; Finney Rutten LJ; Shapiro S; Tilburt JC; Master Z
    Stem Cell Reports; 2023 Aug; 18(8):1549-1554. PubMed ID: 37557072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marijuana in the Workplace: Guidance for Occupational Health Professionals and Employers: Joint Guidance Statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine.
    Phillips JA; Holland MG; Baldwin DD; Gifford-Meuleveld L; Mueller KL; Perkison B; Upfal M; Dreger M
    Workplace Health Saf; 2015 Apr; 63(4):139-64. PubMed ID: 25862727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.
    Horner C; Tenenbaum E; Sipp D; Master Z
    NPJ Regen Med; 2018; 3():5. PubMed ID: 29479481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RxLegal: A Rapid Review of Right-To-Try.
    Gabay M
    Hosp Pharm; 2018 Jul; 53(4):234-235. PubMed ID: 30038441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders.
    Matthews KR; Iltis AS
    BMC Med Ethics; 2015 Nov; 16(1):75. PubMed ID: 26537611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
    Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
    Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical Negligence Determinations, the "Right to Try," and Expanded Access to Innovative Treatments.
    Meyerson D
    J Bioeth Inq; 2017 Sep; 14(3):385-400. PubMed ID: 28634770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unproven stem cell interventions: A global public health problem requiring global deliberation.
    Master Z; Matthews KRW; Abou-El-Enein M
    Stem Cell Reports; 2021 Jun; 16(6):1435-1445. PubMed ID: 34107243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who Stands to Benefit? Right to Try Law Provisions and Implications.
    Kearns L; Bateman-House A
    Ther Innov Regul Sci; 2017 Mar; 51(2):170-176. PubMed ID: 30231728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions.
    Weiss DJ; Turner L; Levine AD; Ikonomou L
    Cytotherapy; 2018 Feb; 20(2):165-168. PubMed ID: 29239793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The US Opioid Crisis: Current Federal and State Legal Issues.
    Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
    Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconciling States' "Right to Try" Legislation and FDA's Expanded Access Program: Legal Issues.
    Shapiro RS
    Ther Innov Regul Sci; 2017 Mar; 51(2):153-156. PubMed ID: 30231723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Illegal migrants and sanctions against employers in the United States: the anti-model of state laws].
    Ardittis S
    Studi Emigr; 1984 Jun; 21(74):153-74. PubMed ID: 12313240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free to Choose: A Moral Defense of the Right-to-Try Movement.
    Brodrick M
    J Med Philos; 2020 Jan; 45(1):61-85. PubMed ID: 31922578
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.